AstraZeneca的Imfinzi 用于欧盟早期胃癌,显示在试验中近70%的3年存活。 AstraZeneca's Imfinzi获批 for early gastric cancer in EU, showing nearly 70% three-year survival in trial.

AstraZeneca's Imfinzi已被欧盟批准为首例早期胃癌和胃癌的临死性免疫疗法, AstraZeneca's Imfinzi has been approved in the EU as the first perioperative immunotherapy for early gastric and gastroesophageal cancers, based on the phase three Matterhorn trial showing improved event-free and overall survival. 疗养院使用Imfinzi在手术前后进行化疗,之后只有Imfinzi一人。 The regimen uses Imfinzi with chemotherapy before and after surgery, followed by Imfinzi alone. 治疗提供了近70%的3年存活率,尽管有标准疗法,但仍解决了高复发率问题。 The treatment offers nearly 70% three-year survival, addressing high recurrence rates despite standard therapy. 这标志着AstraZeneca在欧洲第三次接受性能免疫疗法。 This marks AstraZeneca’s third perioperative immunotherapy approval in Europe.